

**16-NOV-2018 6:11
OPEN STUDIES IRB REPORT**

06:10 Friday, November 16, 2018 1

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs	
BREAST	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	434	209	
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	263	130	
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	463	210	
	S1706	Breast, Inflammatory, RT +/- Olaparib	12-SEP-18	0	20	
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	268	119	
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	469	242	
	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	227	
	A221405	Breast, ET interruption, Pregnancy Outcomes	15-OCT-15	0	53	
	B51	Breast, Regional Nodal XRT	22-AUG-13	394	208	
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	439	185	
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	71	24	
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	304	176	
	EA1151	Brst, Tomosynthesis Mammographic Screening	06-JUL-17	0	75	
	NRGBR002	Brst, OMBC, II-III, SoC +/- SBRT and/or SA	24-DEC-14	0	135	
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	331	172	
	NRGBR005	Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	13-APR-17	0	18	
	CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	13	18
		S1417CD	Colorectal, Cost Cohort Study	13-MAY-16	115	29
S1703		Met Breast, STM-monitoring v Usual Care	16-JUL-18	0	47	
A011104		Preoperative Breast MRI	21-FEB-14	137	45	
A191402C		PROS, Testing Decision Aids for Minority Men	14-JUL-17	0	10	
EAQ162CD		CCD, Financial Burden, Colon & Rectal Cancer	17-MAY-18	0	12	
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	307	159	
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	351	142	
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	295	109	
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	261	119	
	EAY131	MATCH	12-AUG-15	370	207	
GI	S1613	mCRC, Adv/Met, TP vs CETIRI	09-OCT-17	0	127	
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	36	
	A021502	Colon, Stg III, Chemo +/- Atezol, ATOMIC	12-SEP-17	0	45	
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	197	77	
	EA2161	PANC, Adv Rapalog Resistant PNETs, MLN0128	01-FEB-17	0	7	
	EA2165	Anal, Stg II-III, Nivolumab after CMT	13-APR-18	0	11	
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	157	

**16-NOV-2018 6:11
OPEN STUDIES IRB REPORT**

06:10 Friday, November 16, 2018 2

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	352	148
	NRGGI004	Colorectal, Stg IV, dMMR Immuno-Therapy	07-NOV-17	0	41
GU	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	210	88
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	173	68
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	189	88
	S1802	Pros, Stg IV, SST +/- Surg/RT to Primary Tum	17-SEP-18	0	36
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	55	34
	A031501	Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	21-SEP-17	0	110
	EA8143	RCC, HR, Surg +/- Nivolumab (PROSPER)	02-FEB-17	0	142
	EA8153	Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	08-FEB-18	0	19
	NRGGU002	Pros, RT + ADT After RP +/- Adj Docetaxel	30-DEC-16	0	118
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	173
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	1	1
	S1712	CML, chronic phase, TKI +/- Ruxolitinib	20-JUL-18	0	48
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	168	83
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	133	70
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	194	76
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	435	204
	S1400F	Non-Match: MEDI4736 + Tremelimumab	02-OCT-17	0	207
	S1619	Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	03-NOV-17	0	26
	S1701	Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	09-AUG-18	0	19
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	248
	A151216	ALCHEMIST0 - screening	06-FEB-14	478	249
	C30610	SCLC, Thoracic RT	21-MAR-08	157	93
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	469	247
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	448	244
	EA5161	Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo	02-MAY-18	0	124
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	328	149
LYMPH	S1608	FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	10-AUG-17	0	103
	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	153	68
	EA4151	Lymph, AHCT +/-Ritux, MRD Neg	29-AUG-17	0	59
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	220	98
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	89	42

**16-NOV-2018 6:11
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	S1607	MELAN, Adv, T-VEC, MK-3475	02-OCT-17	0	17
	S1616	MELAN, Adv, Ipilimumab ± Nivolumab	17-JUL-17	0	95
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	348	141
	EA6141	Melan, Adv, Nivolumab+Ipi ± Sargmostim	01-MAR-16	218	95
MMYEL	S1702	AL Amyloidosis, Relapsed, Isatuximab	08-MAR-18	0	58
	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	287	127
OTHER	A091304	Adv Sarc, MLN0128 v Pazopanib, Phi/II	26-JAN-15	233	81
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	85	26
	A091401	Sarc,	18-JUN-15	171	72
	A091404	HN, AR+, Enzalutamide	25-SEP-15	76	40
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	67
	EAF151	Brain, GBM, Bev, Blood Volume	14-APR-17	0	33
	EAQ152	Communication & education in tumor profiling	26-SEP-16	168	77
	G0263	Cerv, Stg I/IIA, adjv RT vs chemoRT	12-APR-10	0	74
	N0577	BRN, Glio, Tem vs Tem+RT vs RT+PVC	22-SEP-09	160	77
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	97
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	324	141
	NRGGY009	Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev	12-MAY-17	0	6
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	197	72
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	204	82
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	247	116
PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	153	64
	A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	12	5
SURV	S1316	Compar. Effectiv. Trial for MBO	01-AUG-14	4	7
	S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol	15-SEP-17	0	98
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	44
	EA9131	Leuk, Strategy to decrease early APL deaths	16-AUG-17	0	24
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	86	34
	A221505	Brst, Hypofractionated Post Mast Rad	01-FEB-18	0	17
	NRGGU003	Pros, Post-Prostatectomy HYPOR vs COPORT	28-JUL-17	0	116